Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Size: px
Start display at page:

Download "Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011"

Transcription

1 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011

2 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai Motor s management, our use of the words expect, anticipate, project, estimate, forecast, objective, plan, goal, outlook, target, pursue and similar expressions is intended to identify forward looking statements. The financial data discussed herein are presented on a preliminary basis before the audit from Independent Auditor; final data will be included in HMC s Independent auditors report. While these statements represent our current judgment on what the future may hold, and we believe these judgments are reasonable, actual results may differ materially due to numerous important factors. Such factors include, among others, the following : changes in economic conditions, currency exchange rates or political stability; shortages of fuel, labor strikes or work stoppages; market acceptance of the corporation s new products; significant changes in the competitive environment; changes in laws, regulations and tax rates; and the ability of the corporation to achieve reductions in cost and employment levels to realize production efficiencies and implement capital expenditures at levels and times planned by management. We do not intend or assume any obligation to update any forward-looking statement, which speaks only as of the date on which it is made.

3 Table of Contents Sales Summary Financial Summary Revenue & Profit Analysis Appendix

4 Sales Summary Retail Sales Wholesale

5 Sales Summary : Retail Sales 1Q Q 2011 (Unit : 1,000 vehicles) -0.8% +29.3% +27.9% +0.01% Korea EU China +10.0% US +4.7% Others 1Q 2010 Global Sales 1Q 2011 Source : Company data (Includes shipment of LCV / Excludes CKD sales) 5

6 Sales Results by Key Region Korea US US (Unit : 1,000 vehicles) EU EU 48.1% 46.0% 4.4% 4.7% 2.7% 2.8% -0.8% % % Q Q 2011 PC RV CV M/S 1Q Q 2011 PC RV M/S 1Q Q 2011 PC RV CV M/S Unit sales in 10.1Q slightly declined due to the high base effect (YOY 0.8% ) Large-car segment sales increased with introduction of HG (YOY 60% ) Launched MD successfully while YF continues to maintain high level of customer demand Lowest level of incentive spending ( 11.1Q : $1,117 / units) Despite of market demand decrease in 1Q, sales of ix20 and ix 35 increased Sales growth in Germany (YoY 41% ) mitigated demand decrease in EU Source : Company data / Automotive News / ACEA 6

7 Sales Summary : Wholesale Sales Volume by by Plant Sales Mix Mix by by Segment (Unit : 1,000 vehicles) % 919 7% 8% KOREA CHINA INDIA 17% 17% 18% 18% CV RV US CZECH TURKEY Mid-Large PC Small PC RUSSIA 58% 57% 1Q Q Q Q 2011 Sales volume by plant (Wholesale basis) 7

8 Financial Summary (K-IFRS) Statement of Income Financial Summary by division Statement of Financial Position Cash Flow Highlights

9 Consolidated Statement of Income (KRW Billion) 1Q Q 2011 Change Sales Revenue Gross Profit Margin (%) SG&A Portion (%) Other Operating Income Operating Profit Margin (%) Recurring Profit Margin (%) Net Profit Margin (%) Depreciation Amortization EBITDA 15,021 3, , , , , ,806 18,233 4, , , , , ,367 3, Consolidated Statement of Income (K-IFRS), Business results of BHMC is accounted in equity income accounting Net Profit includes non-controlling interest 9

10 Financial Summary by Division (KRW Billion) 1Q Q 2011 Change Sales Revenue 15,021 18,233 3,212 Automotive 12,511 15,541 3,031 Finance 1,665 1, Other Operating Profit 1,256 1, Automotive 899 1, Finance Other Consolidation adjustment Consolidated Statement of Income (K-IFRS) 10

11 Consolidated Statement of Financial Position (KRW Billion) Q 2011 Change Assets 94,714 97,808 3,094 Current Assets 43,520 47,514 3,994 Cash & Cash Equivalents* 13,638 15,642 2,004 Liabilities 61,826 63,302 1,476 Current Liabilities 31,446 32, Short & Long-Term Debt 38,596 39, Warranty Provision 5,986 6, Equity 32,888 34,506 1,618 Current Ratio (%) Debt / Equity Ratio (%) Net Cash 24,959 23,590 1,369 EBITDA / Interest Expense 10.6 x 17.2 x Consolidated Statement of Financial Position (K-IFRS) Cash & Cash Equivalents : Cash & cash equivalents + Short-term financial instruments 11

12 Consolidated Cash Flow Highlights (KRW Billion) + 1, ,357 6,216 Depreciation / Amortization Tangible / Intangible asset Dividend payment Other Net Income Beginning Cash Balance Ending Cash Balance Consolidated Cash Flow Highlights (K-IFRS) Above figures includes consolidation adjustments by business division (Automotive / Finance / Others) 12

13 Revenue & Profit Analysis Sales Revenue Analysis COGS and SG&A Net Non-Operating Income

14 Sales Revenue Analysis Sales Revenue Positive // Negative Contributors (KRW Billion) Positive Factors 15,021 18, ,212 ( 21.4% ) Improved overseas sales & mix : Unit sales : + 9.2% (842, ,130) 15,541 12,511 Negative Factors KRW appreciation against the USD USD / KRW 1, ,119.3 (2.2% ) 1,665 1, Q Q 2011 KRW appreciation against the EUR EURO / KRW 1, ,540.4 (2.3% ) Automotive Finance Others Consolidated sales revenue excludes sales revenue of BHMC Consolidated sales revenue by business division (Automotive / Finance / Others) 14

15 COGS and SG&A COGS 77.7% 77.2% SG&A and Other Operating Income // Expense (% of Revenue) (% of Revenue, KRW billion) SG & A Salary & wage Marketing Expense Sales warranties Warranty Provision other Other income/ expense (net) F/X transactions 2,165 2, % 5.4% 0.5% 1.3% 4.6% 10.8% 2, % 4.8% 0.4% 1.6% 4.0% 2,434 other % 0.1% 0.1% 0.5% 105 1Q Q Q Q 2011 Consolidated Statement of Income (K-IFRS) 15

16 Net Non-Operating Income (KRW Billion) Financial Income Financial Expense Equity Earnings Q Q Q Q Q Q Q 2010 : Net Non-Operating Income 1Q 2011 : Consolidated Statement of Income (K-IFRS) 16

17 Appendix Changes in accounting policy - Major changes under K-IFRS - Scope of consolidation changes - K-IFRS vs. K-GAAP (Standalone) Overseas Plant Operations

18 Major changes under K-IFRS Changes under K-IFRS Scope of Consolidation Recognition of Account Receivable Employee Benefit Accrued Liabilities Valuation Borrowing Cost Investment Property - Consolidation standard : more than 50% of equity or owns effective management control [largest shareholder with more than 30% shareholding NOT consolidated, SPC consolidated] - Account receivables with recourse to drawers (D/A, L/C, etc) are recognized as liabilities. Previously under K-GAAP they were not recognized as liabilities. - Use actuarial approach to determine amount of allowance for severance liability and long-term employment benefit. - The provision value is discounted with current market discount. - From the date of implementation of the new Standard, Borrowing costs related to the acquisition, construction or production of qualifying asset are capitalize as part of the cost of that asset. - Property held to earn rental income or profit taking purpose are classified as investment property. Previously under K-GAAP, it was classified as tangible asset. 18

19 Scope of consolidation changes Scope of consolidation under K-IFRS : 74 companies (Equity Method affiliates: 33 companies) Consolidation Company Name included (Total 23 companies) Hyundai ngv CARNES HMJ R&D Center Inc Hyundai Capital Europe GmbH Rotem Equiptments (Beijing), etc. excluded (Total 58 companies) Kia Motor & 23 subsidiaries Hyundai HYSCO & 8 subsidiaries Hyundai Dymos & 3 subsidiaries Hyundai WIA & 5 subsidiaries Hyundai Powertech & 2 subsidiaries Hyundai Commercial, etc. Total Number of consolidated companies under K-GAAP (as of end of 2010): 95 companies (Equity Method affiliates: 42 companies) 19

20 K-IFRS vs. K-GAAP (Standalone) (KRW Billion) 1Q 2010 (K-GAAP) 1Q 2010 (K-IFRS) 1Q 2011 (K-IFRS) 비고 Sales Revenue 8, , ,326.2 Gross Profit 1, , ,279.1 Margin (%) SG&A 1, , ,384.7 Portion (%) Other Operating Income Operating Profit Margin (%) Recurring Profit 1, ,209.7 Margin (%) Net Profit 1, Margin (%)

21 Overseas Plant Operations

22 Overseas Plant : HMMA & BHMC (Unit : 1,000 vehicles / KRW Billion) US US Plant (HMMA) China Plant (BHMC) Sales Volume Revenue Sales Volume Revenue Sonata(YF) Elantra(MD) Santa-Fe(CM) Others Q 11 1Q Chg Elantra Tucson Sonata Others Q 11 1Q Chg Revenue 1,368 1,558 14% Revenue 2,262 2,933 30% Q Q Q Q 2011 Above figures are standalone results base 22

23 Overseas Plant : HMI & HAOS (Unit : 1,000 vehicles / KRW Billion) India Plant (HMI) Turkey Plant (HAOS) Sales Volume Revenue Sales Volume Revenue I10 PB Santro Others Accent Matrix i Revenue 10 1Q 1, Q 1,238 Chg -5% 20 Revenue 10 1Q Q 292 Chg 56% Q '10 1Q '11 1Q '10 1Q '11 Above figures are standalone results base 23

24 Overseas Plant : HMMC & HMMR (Unit : 1,000 vehicles / KRW Billion) Czech Plant (HMMC) Russia Plant (HMMR) Sales Volume Revenue Sales Volume Revenue i30 JC YN RBr Q 11 1Q Chg 10 1Q 11 1Q Chg Revenue % Revenue Q '10 1Q '11 1Q '10 1Q '11 Above figures are standalone results base 24

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

Summary Statement of Financial Position (consolidated)

Summary Statement of Financial Position (consolidated) 2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Consolidated: Financial Summary

Consolidated: Financial Summary FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating

More information

Endesa 1Q 2017 Results 09/05/2017

Endesa 1Q 2017 Results 09/05/2017 Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures

More information

Welcome to LG Electronics

Welcome to LG Electronics Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

1Q 2014 Earnings Release

1Q 2014 Earnings Release 1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains

More information

Results Briefing. 15 ~ 17 May 2007

Results Briefing. 15 ~ 17 May 2007 Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights

More information

First Quarter Results to March 31, Shire plc April 25, 2008

First Quarter Results to March 31, Shire plc April 25, 2008 First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1- BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

THIRD QUARTER REPORT 2011 (UNAUDITED)

THIRD QUARTER REPORT 2011 (UNAUDITED) THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor

More information

Presentation of. Burgdorf, 1 st November 2012

Presentation of. Burgdorf, 1 st November 2012 Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,

More information

Woongjin Coway. 1Q 12 IR Presentation

Woongjin Coway. 1Q 12 IR Presentation Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

Investor Relations 1Q 2017

Investor Relations 1Q 2017 Investor Relations 1Q 2017 History Leading Authentic Sports Brand Inspired by the Style, Elegance and Passion of our Italian Heritage Founded by FILA brothers in Biella, Italy Established FILA Korea FILA

More information

M e d i a s e t G r o u p

M e d i a s e t G r o u p M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

SWEDISH MATCH RESULTS PRESENTATION Q3 2017

SWEDISH MATCH RESULTS PRESENTATION Q3 2017 SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

APPLIANCE TELECOMMUNICATIONS

APPLIANCE TELECOMMUNICATIONS May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders Contact: Investor Relations: Bob Bannon (336) 741-3359 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2016-22 RAI reports strong 2Q16 performance

More information

1Q2017 法人說明會 Jun. 9, 2017

1Q2017 法人說明會 Jun. 9, 2017 1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic

More information

TELECONFERENCE Q August 2015

TELECONFERENCE Q August 2015 TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

Group financial results for the first quarter 2008

Group financial results for the first quarter 2008 Helmut Perlet, Member of the Board of Management Group financial results for the first quarter 2008 Journalists Conference Call May 9th, 2008 Group: robust earnings in stormy weather (EUR mn) Quarterly

More information

SWEDISH MATCH RESULTS PRESENTATION Q4 2018

SWEDISH MATCH RESULTS PRESENTATION Q4 2018 SWEDISH MATCH RESULTS PRESENTATION Q4 2018 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total

More information

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007 Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period

More information

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of

More information

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland

More information

Q Investor Kit January December 2015

Q Investor Kit January December 2015 Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local

More information

FY2016 1H Results. Cookpad Inc.

FY2016 1H Results. Cookpad Inc. FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising

More information

Leading Intimate Healthcare. Investor presentation Q1 2007/08

Leading Intimate Healthcare. Investor presentation Q1 2007/08 Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1

More information

Telekom Austria Group Results for the First Quarter May 16, 2007

Telekom Austria Group Results for the First Quarter May 16, 2007 Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

METVIX PDT ON THE MARKET IN GERMANY AND UK

METVIX PDT ON THE MARKET IN GERMANY AND UK METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone

More information

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating

More information

JT Group Consolidated Financial Results 2018 First Quarter Results

JT Group Consolidated Financial Results 2018 First Quarter Results JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

Review of Half Year 2010

Review of Half Year 2010 Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr. MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its

More information

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor

More information

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

MARCH 2014 RESULTS PRESENTATION Madrid, 2014 MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted

More information

ELICA 2012 Q3 RESULTS. November 14,

ELICA 2012 Q3 RESULTS. November 14, ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information

Business Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.

Business Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd. Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

Valneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company s Trend towards EBITDA Break-even

Valneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company s Trend towards EBITDA Break-even Valneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company s Trend towards EBITDA Break-even Financial performance of commercial products continued to improve in the second

More information

Total Face Group Limited

Total Face Group Limited Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Interim Report 1 January September 2017

Interim Report 1 January September 2017 2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights

More information

Morgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc

Morgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc Morgan Stanley CEOs Unplugged January 3, 2008 Matthew Emmens, CEO Shire plc Introduction Strategy on track Excellent third quarter results Strong product sales reflecting good results and successful product

More information

SWEDISH MATCH INVESTOR KIT Q4 2016

SWEDISH MATCH INVESTOR KIT Q4 2016 SWEDISH MATCH INVESTOR KIT Q4 2016 A look at the quarter 2 Q4 HEADLINE BULLETS Sales increased by 6 percent to 3,957 MSEK (3,719) for the fourth quarter and by 7 percent to 15,551 MSEK (14,486) for the

More information

Nobel Biocare Group Full Year Report 2005

Nobel Biocare Group Full Year Report 2005 Nobel Biocare Group Full Year Report 2005 Zurich, Switzerland 9 February 2006 Nobel Biocare again outpaces market with record revenue growth of 25% and an EBIT margin of 33.5% in 2005 Revenue for the full

More information

Supplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016

Supplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016 Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic

More information

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183) Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating

More information

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

ThromboGenics Business Update H1 2018

ThromboGenics Business Update H1 2018 Press release 6 September 2018 Regulated Information ThromboGenics Business Update H1 2018 Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion

More information

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183) Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

For personal use only

For personal use only FY2015 Half Year Results Presentation 6 months ended 30 September 2014 24 28 November 2014 1 First half result highlights H1 FY15 (6 months to 30 September 2014) PCP CC 1 Operating profit +8% +64% RAC

More information

Investor Presentation. Q April 26, 2018

Investor Presentation. Q April 26, 2018 Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities

More information

Zealand Pharma A/S Interim report for Q (un-audited)

Zealand Pharma A/S Interim report for Q (un-audited) Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and

More information

Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014

Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014 Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014 André Calantzopoulos Chief Executive Officer Philip Morris International Forward-Looking and Cautionary Statements This presentation

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria FINANCIAL TIMES INVESTING IN BULGARIA CONFERENCE Investment Opportunities in Bulgaria The Case of Solvay Sodi Spiros Nomikos CEO of Solvay Sodi

More information

Third Quarter Results to September 30, 2009

Third Quarter Results to September 30, 2009 Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015

PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 KEY MESSAGES AGENDA 1Q 2015 RESULTS 2015 OUTLOOK & TARGETS 1Q 2015 TYRE OVERVIEW APPENDIX 1Q 2015 RESULTS 1 KEY MESSAGES > A solid 1Q 2015 with Premium outperformance

More information

1Q 2015 Results A Positive Start to 2015

1Q 2015 Results A Positive Start to 2015 1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results

More information

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development

More information

Financial Report on Zurich March 28, 2013

Financial Report on Zurich March 28, 2013 Financial Report on 2012 Zurich March 28, 2013 1 Safe Harbour Statement This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information

More information

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance

More information